Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
BMJ Open ; 14(4): e074604, 2024 Apr 12.
Artigo em Inglês | MEDLINE | ID: mdl-38609314

RESUMO

RATIONALE: Intensive care units (ICUs) admit the most severely ill patients. Once these patients are discharged from the ICU to a step-down ward, they continue to have their vital signs monitored by nursing staff, with Early Warning Score (EWS) systems being used to identify those at risk of deterioration. OBJECTIVES: We report the development and validation of an enhanced continuous scoring system for predicting adverse events, which combines vital signs measured routinely on acute care wards (as used by most EWS systems) with a risk score of a future adverse event calculated on discharge from the ICU. DESIGN: A modified Delphi process identified candidate variables commonly available in electronic records as the basis for a 'static' score of the patient's condition immediately after discharge from the ICU. L1-regularised logistic regression was used to estimate the in-hospital risk of future adverse event. We then constructed a model of physiological normality using vital sign data from the day of hospital discharge. This is combined with the static score and used continuously to quantify and update the patient's risk of deterioration throughout their hospital stay. SETTING: Data from two National Health Service Foundation Trusts (UK) were used to develop and (externally) validate the model. PARTICIPANTS: A total of 12 394 vital sign measurements were acquired from 273 patients after ICU discharge for the development set, and 4831 from 136 patients in the validation cohort. RESULTS: Outcome validation of our model yielded an area under the receiver operating characteristic curve of 0.724 for predicting ICU readmission or in-hospital death within 24 hours. It showed an improved performance with respect to other competitive risk scoring systems, including the National EWS (0.653). CONCLUSIONS: We showed that a scoring system incorporating data from a patient's stay in the ICU has better performance than commonly used EWS systems based on vital signs alone. TRIAL REGISTRATION NUMBER: ISRCTN32008295.


Assuntos
Readmissão do Paciente , Medicina Estatal , Humanos , Mortalidade Hospitalar , Unidades de Terapia Intensiva , Cuidados Críticos
2.
J Crit Care ; 60: 72-78, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32763777

RESUMO

PURPOSE: New onset atrial fibrillation (NOAF) in critically ill patients has been associated with increased short-term mortality. Analyses that do not take into account the time-varying nature of NOAF can underestimate its association with hospital outcomes. We investigated the prognostic association of NOAF with hospital outcomes using competing risks methods. MATERIALS AND METHODS: We undertook a retrospective cohort study in three general adult intensive care units (ICUs) in the UK from June 2008 to December 2015. We excluded patients with known prior atrial fibrillation or an arrhythmia within four hours of ICU admission. To account for the effect of NOAF on the rate of death per unit time and the rate of discharge alive per unit time we calculated subdistribution hazard ratios (SDHRs). RESULTS: Of 7541 patients that fulfilled our inclusion criteria, 831 (11.0%) developed NOAF during their ICU admission. NOAF was associated with an increased duration of hospital stay (CSHR 0.68 (95% CI 0.63-0.73)) and an increased rate of in-hospital death per unit time (CSHR 1.57 (95% CI 1.37-1.1.81)). This resulted in a strong prognostic association with dying in hospital (adjusted SDHR 2.04 (1.79-2.32)). NOAF lasting over 30 min was associated with increased hospital mortality. CONCLUSIONS: Using robust methods we demonstrate a stronger prognostic association between NOAF and hospital outcomes than previously reported.


Assuntos
Fibrilação Atrial/mortalidade , Cuidados Críticos/métodos , Mortalidade Hospitalar , Unidades de Terapia Intensiva , Admissão do Paciente , Idoso , Fibrilação Atrial/epidemiologia , Comorbidade , Estado Terminal , Feminino , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Alta do Paciente , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Reino Unido/epidemiologia
4.
Hematol J ; 4(1): 54-6, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12692521

RESUMO

Capillary leak syndrome (CLS) commonly occurs in the intensive care setting. CLS is seen in conditions such as septic shock or may result from conditions such as multitrauma and pancreatitis, which result in the systemic inflammatory response syndrome (SIRS). We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously. We discuss how these patients management differs from other intensive care unit patients with CLS and how it is important to diagnose this condition early in haematological oncology cases.


Assuntos
Síndrome de Vazamento Capilar/induzido quimicamente , Fator Estimulador de Colônias de Granulócitos/efeitos adversos , Mobilização de Células-Tronco Hematopoéticas/efeitos adversos , Leucemia Mielogênica Crônica BCR-ABL Positiva/complicações , Mieloma Múltiplo/complicações , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Síndrome de Vazamento Capilar/tratamento farmacológico , Síndrome de Vazamento Capilar/fisiopatologia , Terapia Combinada , Cuidados Críticos , Ciclofosfamida/uso terapêutico , Dexametasona/administração & dosagem , Doxorrubicina/administração & dosagem , Dispneia/etiologia , Edema/etiologia , Edema/fisiopatologia , Fasciite Necrosante/etiologia , Evolução Fatal , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Hidroxiureia/administração & dosagem , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Modelos Biológicos , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/terapia , Transplante de Células-Tronco de Sangue Periférico , Talidomida/uso terapêutico , Vasculite Leucocitoclástica Cutânea/induzido quimicamente , Vincristina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA